Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...

Schizophrenia is generally a chronic and disabling mental illness. Pharmacological therapy, which is used for relief of acute psychotic episodes and prevention of subsequent relapse, is essential for ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Chronic cocaine use can induce cocaine-related cerebropathy, particularly in patients with increased risk for neurodegenerative processes. Chronic cocaine use is associated with an increased risk for ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class ...

This case highlights vitamin E’s potential as an effective adjunct treatment for patients with antipsychotic-induced motor symptoms resistant to standard therapies. Vitamin E has shown significant ...